Tulisokibart

DB18719InvestigationalProtein Based Therapies

PRA023 is a humanized monoclonal antibody directed to vascular endothelial growth inhibitor, also known as tumour necrosis factor (TNF)-like ligand 1A (TL1A) and TNF superfamily member 15. It is being... It is being investigated for ulcerative colitis.

Code names: MK-7240 · PRA-023

Resolves to

Compound

UNIION09TCS5H3CAS2648504-55-4

Targets

O95150TNFSF15

What you can answer from here — as of April 23, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

13Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Tulisokibart, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account